Key result
GDMT reinforcement linked to ~77% lower HF rehospitalization risk in HFrEF patients on pimobendan.
Why the study?
Heart disease is a leading cause of death in Japan, creating an urgent need for effective treatment strategies for heart failure patients.
Does reinforcement of GDMT reduce rehospitalization rates in heart failure patients receiving pimobendan?
Cohort (n=111)
No
Does reinforcement of GDMT reduce rehospitalization rates in heart failure patients receiving pimobendan?
Reinforcing guideline-directed medical therapy in heart failure patients treated with pimobendan may reduce rehospitalization rates, especially in those with reduced ejection fraction.
Supports GDMT optimization in pimobendan-treated HFrEF; leaves open causal confirmation in randomized trials.
Heart failure is a critical global public health issue, significantly impacting patients' quality of life and healthcare costs. In Japan, heart diseases rank among the leading causes of death, highlighting the urgent need for effective treatment strategies for heart failure patients. In recent years, guideline-directed medical therapy (GDMT) has been increasingly recommended, with particular focus on the use and optimization of specific therapeutic agents. Our study demonstrated that the reinforcement of GDMT in heart failure patients receiving pimobendan may contribute to a reduction in rehospitalization rates. This effect was particularly pronounced in patients with reduced ejection fraction (rEF), emphasizing the pivotal role of GDMT in heart failure management. This article explores the impact of the combination of pimobendan and GDMT on the prognosis of patients with heart failure.
No takes yet. Share an insight, caveat, or question.
Iwade et al. (2025) conducted a cohort in Heart failure (n=111). Guideline-directed medical therapy (GDMT) reinforcement vs. No GDMT reinforcement was evaluated on Heart failure rehospitalization (in patients with reduced ejection fraction) (HR 0.23, 95% CI 0.07-0.77, p=0.017). Guideline-directed medical therapy reinforcement significantly reduced the risk of heart failure rehospitalization (HR 0.23) in patients with reduced ejection fraction receiving pimobendan.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: